Lack of Association between an XRCC1 Gene Polymorphism and Colorectal Cancer Survival in Thailand

  • Siewchaisakul, Pallop (Epidemiology and Biostatistics Section, Faculty of Public Health, Khon Kaen University) ;
  • Suwanrungruang, Krittika (Cancer Unit, Faculty of Medicine, Khon Kaen University) ;
  • Poomphakwaen, Kirati (Program of Public Health, Department of Applied Science, Faculty of Science and Technology, Loei Rajabhat University) ;
  • Wiangnon, Surapon (Department of Paediatrics, Faculty of Medicine, Khon Kaen University) ;
  • Promthet, Supannee (Epidemiology and Biostatistics Section, Faculty of Public Health, Khon Kaen University)
  • Published : 2016.06.01


Background: Colorectal cancer (CRC) is one of the most common causes of death worldwide and in Thailand. The X-ray repair cross-complementary protein 1 (XRCC1) is required for efficient DNA repair. The effects of this gene on survival in colorectal cancer remain controversial and have not been reported in Thailand. The aim of this study was to investigate the association of the XRCC1 gene with survival of colorectal cancer patients in a Thai population. Materials and Methods: Data and blood samples were collected from 255 newly diagnosed and pathologically confirmed CRC patients who were recruited during the period 2002 to 2006 and whose vital status was followed up until 31 October, 2014. Real-time PCR-HRM was used for genotype identification. The Kaplan-Meier method, the log-rank test, and Cox proportional hazard regression were used to estimate cumulative survival curves and compare various survival distributions and adjusted hazard ratios. Results: Most of the cases were males, and the median age was 55 years. The median survival time was 2.43 years. The cumulative 1-, 3-, 5-, 7-, and 10 year survival rates were 76.70%, 39.25%, 26.50%, 16.60% and 3.56%, respectively. After adjustment, female gender, ages 50-59 and ${\geq}60years$, tumour stage III+IV, a signet-ring cell carcinoma, and poor differentiation had significant associations with increased risk of CRC death. While the XRCC1 Arg/Arg homozygote appeared to be a risk factor for CRC death, the association was not significant. Conclusions: The genetic variant in the XRCC1 may not be associated with the survival of CRC patients in Thailand. Further studies are needed to verify our findings.


  1. Al-Ahwal MS, Shafik YH, Al-Ahwal HM (2013). First national survival data for colorectal cancer among Saudis between 1994 and 2004: what's next? BMC Public Health, 13, 73.
  2. Berberoglu U (2004). Prognostic significance of total lymph node number in patients with T1-4N0M0 colorectal cancer. Hepato-Gastroenterol, 51, 1689-93.
  3. Bewick MA, Conlon MSC, Lafrenie RM (2006). Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer. J Clin Oncol, 24, 5645-51.
  4. Brem R, Hall J (2005). XRCC1 is required for DNA single-strand break repair in human cells. Nucleic Acids Res. 3, 2512-20.
  5. Dai Q, Luo H, Li XP, et al (2015). XRCC1 and ERCC1 polymorphisms are related to susceptibility and survival of colorectal cancer in the Chinese population. Mutagenesis:geu088.
  6. Dignam JJ, Ye Y, Colangelo L, et al (2003). Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized Trials. J Clin Oncol, 21, 413-20.
  7. Elsaleh H, Joseph D, Grieu F, et al (2000). Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet, 355, 1745-50.
  8. Ferlay J, Soerjomataram I, Dikshit R, et al (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136, 359-86.
  9. Goode EL, Ulrich CM, Potter JD (2002). Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiology Biomarkers Prevent, 11, 1513-30.
  10. Grimminger PP, Brabender J, Warnecke-Eberz U, et al (2010). XRCC1 Gene polymorphism for prediction of response and prognosis in the multimodality therapy of patients with locally advanced rectal cancer. J Surgical Res, 164, 61-6.
  11. Halvorsen TB, Seim E (1989). Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J Clinical Pathol, 42, 162-6.
  12. Kabzinski J, Przybylowska K, Mik M, et al (2010). An Association of ARG399GLN Polymorphism of XRCC1 gene with a risk of colorectal cancer. Polish J Surg, 82, 677-680.
  13. Khuhaprema T, Srivatanakul P (2008). Colon and rectum cancer in Thailand: an overview. Japanese J Clin Oncol, 38, 237-43.
  14. Kim JG, Chae YS, Sohn SK, et al (2010). IVS10+12A>G polymorphism in hMSH2 gene associated with prognosis for patients with colorectal cancer. Ann Oncol, 21, 525-9.
  15. Koo JH, Jalaludin B, Wong SKC, et al (2008). Improved survival in young women with colorectal cancer. Am J Gastroenterol, 103, 1488-95.
  16. Lai CY, Hsieh LL, Sung FC, et al (2013). Tumor site- and stagespecific associations between allelic variants of glutathione s-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. PLoS ONE, 8, e69039.
  17. Laohavinij S, Maneechavakajorn J, Techatanol P (2010). Prognostic factors for survival in colorectal cancer patients. J Med Associat Thailand Chotmaihet Thangphaet, 93, 1156-66.
  18. Li F, Lai M (2009). Colorectal cancer, one entity or three. J Zhejiang University Science B, 10, 219-29.
  19. Liu B, Wei J, Zou Z, et al (2007). Polymorphism of XRCC1 predicts overall survival of gastric cancer patients receiving oxaliplatin-based chemotherapy in Chinese population. European J Human Genetics, 15, 1049-53.
  20. Malvezzi M, Bertuccio P, Rosso T, et al (2015). European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol, mdv001.
  21. Miao J, Zhang X, Tang Q-L, Wang X-Y, Kai L (2012). Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy. Asian Pac J Cancer Prev, 13, 5007-10.
  22. Nitsche U, Zimmermann A, Spath C, et al (2013). Mucinous and signet-ring cell colorectal cancers differ from classical adenocarcinomas in tumor biology and prognosis. Ann Surg, 258, 775-83.
  23. O'Connell JB, Maggard MA, Ko CY (2004). Colon cancer survival rates with the new american joint committee on cancer sixth edition staging. J National Cancer Institute 96, 1420-5.
  24. Poomphakwaen K, Promthet S, Suwanrungruang K, et al (2014). XRCC1 gene polymorphism, diet and risk of colorectal cancer in Thailand. Asian Pac J Cancer Prevent, 15, 7479-7486.
  25. Pourhoseingholi MA (2012). Increased burden of colorectal cancer in Asia. World J Gastrointestinal Oncol, 4, 68.
  26. Putthanachote N, Promthet S, Suwanrungruan K, et al (2014). XRCC1 gene polymorphism, clinicopathological characteristics and stomach cancer survival in Thailand. Asian Pac J Cancer Prev, 16, 6111-6.
  27. Rahib L, Smith BD, Aizenberg R, et al (2014). Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res, 74, 2913-21.
  28. Schetter AJ, Leung S, Sohn JJ, et al (2008). MIcrorna expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA, 299, 425-36.
  29. Shen W, Chen H, Liu P (2011). XRCC1 polymorphisms and pancreatic cancer: a meta-analysis. Chinese J Cancer Res, 23, 165-70.
  30. Sriamporn S, Black RJ, Sankaranarayanan R, et al (1995). Cancer survival in Khon Kaen province, Thailand. Int J Cancer, 61, 296-300.
  31. Takebayashi Y, Aklyama S, Yamada K, Akiba S, Aikou T (1996). Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer, 78, 226-31.<226::AID-CNCR6>3.0.CO;2-J
  32. Tian Z, Li Y-L, Liu J-G (2013). XRCC1 Arg399Gln polymorphism contributes to increased risk of colorectal cancer in Chinese population. Molecular Biology Reports, 40, 4147-51.
  33. Watanabe T, Wu T-T, Catalano PJ, et al (2001). Molecular predictors of survival after adjuvant chemotherapy for colon cancer. New England J Med, 344,1196-1206.
  34. Yeh C-C, Sung F-C, Tang R, Chang-Chieh CR, Hsieh LL (2007). Association between polymorphisms of biotransformation and DNA-repair genes and risk of colorectal cancer in Taiwan. J Biomedical Sci 14, 183-93.
  35. Yi L, Xiao-feng H, Yun-tao L, et al (2013). Association between the XRCC1 Arg399gln polymorphism and risk of cancer: evidence from 297 case-control studies. PLoS ONE, 8, 78071.
  36. Yin G, Morita M, Ohnaka K, et al (2012). Genetic polymorphisms of XRCC1, alcohol consumption, and the risk of colorectal cancer in Japan. J Epidemiol, 22, 64-71.
  37. Yoon SM, Hong YC, Park HJ et al (2005). The polymorphism and haplotypes of XRCC1 and survival of non-small-cell lung cancer after radiotherapy. Int J Radiat Oncol Biology Physics, 63, 885-91.
  38. Zeng FR, Ling Y, Yang J, et al (2012). X-ray repair crosscomplementing group 1 Arg399Gln gene polymorphism and susceptibility to colorectal cancer:a meta-analysis. Tumor Biol, 34, 555-563.
  39. Zhang S, Gao F, Luo J, Yang J (2010). Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis. Colorectal Disease, 12, 754-61.
  40. Zhou W, Liu G, Miller DP, et al (2003). Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prevent, 12, 359-65.

Cited by

  1. Association of insertion-deletions polymorphisms with colorectal cancer risk and clinical features vol.23, pp.37, 2017,